Dear E-drug readers,
I published today this comment in The Lancet on the recent decision by the
Indian Patent Office to grant a patent for the hepatitis-C drug sofosbuvir and
the options countries have through compulsory licensing in accessing generic
I hope this is useful and feel free to circulate widely.
Ellen 't Hoen, LLM | Medicines Law & Policy
phone: +31 (0) 6 375 30 700
e-mail: firstname.lastname@example.org twitter:@ellenthoen